Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06390358 · ClinicalTrials.gov registry record · NA
Effects of Remote Cardiac Ischemic Preconditioning
A NA study of Cardiac Function and Preconditioning, sponsored by Jack Rubinstein.
- Recruiting
- Registry status
- NA
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06390358: Recruiting NA study of Cardiac Function and Preconditioning, sponsored by Jack Rubinstein.
NCT06390358 is a NA study of Cardiac Function and Preconditioning that is actively recruiting participants, run by Jack Rubinstein. The registered enrollment target is 24 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06390358, a NA study of Cardiac Function and Preconditioning, is actively recruiting participants, sponsored by Jack Rubinstein.
- RECRUITING
- Registry status
- NA
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
A heart attack occurs when blood flow is disrupted to the heart and is related to both the blockage and flow restoration (reperfusion injury). An occlusion during a heart attack can be cleared (mostly via stents), but there are no methods to decrease reperfusion injury even though animal studies have found that "preconditioning" has powerful protective effects. Through the observation of Jewish men wearing tefillin the investigators have discovered a method of bringing preconditioning to patients at risk for heart attacks. This study will focus on women as the majority of people who wear tefillin (and have been studied) are men.
Conditions Studied
Interventions
- OTHER Tefillin
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2024-05-01 |
| Est. Completion | 2025-05-01 |
| Phase | NA |
What NCT06390358 shows while recruiting
NCT06390358 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Cardiac Function and Preconditioning appearing as the primary indexed condition, and to 1 intervention - of which Tefillin is the first listed.
NCT06390358 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06390358 about?
NCT06390358 is a clinical study titled "Effects of Remote Cardiac Ischemic Preconditioning". A heart attack occurs when blood flow is disrupted to the heart and is related to both the blockage and flow restoration (reperfusion injury). An occlusion during a heart attack can be cleared (mostly via stents), but there are no methods to decrease reperfusion injury even though animal studies hav...
What is the current status of trial NCT06390358?
This trial is currently recruiting. It is a NA study. The enrollment target is 24 participants. The study started on 2024-05-01. Estimated completion is 2025-05-01.
What conditions does trial NCT06390358 study?
This clinical trial studies the following conditions: Cardiac Function and Preconditioning.
What interventions are being tested in trial NCT06390358?
The interventions under investigation include: Tefillin (OTHER).
Who is sponsoring clinical trial NCT06390358?
This trial is sponsored by Jack Rubinstein, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06390358 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06390358's enrollment target sits among peer trials
24 1736th of 2000 higher than 246 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI